Veracyte Statistics
Total Valuation
Veracyte has a market cap or net worth of $1.49 billion. The enterprise value is $1.28 billion.
| Market Cap | 1.49B |
| Enterprise Value | 1.28B |
Important Dates
The next confirmed earnings date is Tuesday, May 7, 2024, after market close.
| Earnings Date | May 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Veracyte has 75.07 million shares outstanding. The number of shares has increased by 1.53% in one year.
| Shares Outstanding | 75.07M |
| Shares Change (YoY) | +1.53% |
| Shares Change (QoQ) | +0.42% |
| Owned by Insiders (%) | 1.15% |
| Owned by Institutions (%) | 97.15% |
| Float | 74.51M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.12 |
| Forward PS | 3.66 |
| PB Ratio | 1.43 |
| P/FCF Ratio | 43.45 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.56 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 37.47 |
Financial Position
The company has a current ratio of 4.66, with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.66 |
| Quick Ratio | 4.21 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.37 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -7.00% and return on invested capital (ROIC) is -8.12%.
| Return on Equity (ROE) | -7.00% |
| Return on Assets (ROA) | -6.50% |
| Return on Capital (ROIC) | -8.12% |
| Revenue Per Employee | $443,007 |
| Profits Per Employee | -$91,293 |
| Employee Count | 815 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 7.42 |
Taxes
| Income Tax | -2.21M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -14.56% in the last 52 weeks. The beta is 1.64, so Veracyte's price volatility has been higher than the market average.
| Beta (1Y) | 1.64 |
| 52-Week Price Change | -14.56% |
| 50-Day Moving Average | 22.01 |
| 200-Day Moving Average | 24.38 |
| Relative Strength Index (RSI) | 41.65 |
| Average Volume (30 Days) | 665,914 |
Short Selling Information
The latest short interest is 3.64 million, so 4.85% of the outstanding shares have been sold short.
| Short Interest | 3.64M |
| Short Previous Month | 2.74M |
| Short % of Shares Out | 4.85% |
| Short % of Float | 4.88% |
| Short Ratio (days to cover) | 4.98 |
Income Statement
In the last 12 months, Veracyte had revenue of $361.05 million and -$74.40 million in losses. Loss per share was -$1.02.
| Revenue | 361.05M |
| Gross Profit | 248.15M |
| Operating Income | -85.80M |
| Pretax Income | -76.61M |
| Net Income | -74.40M |
| EBITDA | -45.27M |
| EBIT | -76.61M |
| Loss Per Share | -$1.02 |
Balance Sheet
The company has $217.33 million in cash and $12.63 million in debt, giving a net cash position of $204.70 million or $2.73 per share.
| Cash & Cash Equivalents | 217.33M |
| Total Debt | 12.63M |
| Net Cash | 204.70M |
| Net Cash Per Share | $2.73 |
| Equity / Book Value | 1.04B |
| Book Value Per Share | 13.91 |
| Working Capital | 224.38M |
Cash Flow
In the last 12 months, operating cash flow was $44.22 million and capital expenditures -$9.96 million, giving a free cash flow of $34.26 million.
| Operating Cash Flow | 44.22M |
| Capital Expenditures | -9.96M |
| Free Cash Flow | 34.26M |
| FCF Per Share | $0.47 |
Margins
Gross margin is 68.73%, with operating and profit margins of -23.76% and -20.61%.
| Gross Margin | 68.73% |
| Operating Margin | -23.76% |
| Pretax Margin | -21.22% |
| Profit Margin | -20.61% |
| EBITDA Margin | -12.54% |
| EBIT Margin | -21.22% |
| FCF Margin | 9.49% |
Dividends & Yields
Veracyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.53% |
| Shareholder Yield | -1.53% |
| Earnings Yield | -5.00% |
| FCF Yield | 2.30% |
Analyst Forecast
The average price target for Veracyte is $29.00, which is 46.24% higher than the current price. The consensus rating is "Buy".
| Price Target | $29.00 |
| Price Target Difference | 46.24% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Veracyte has an Altman Z-Score of 12.37 and a Piotroski F-Score of 6.
| Altman Z-Score | 12.37 |
| Piotroski F-Score | 6 |